Volume 27, Number 6—June 2021
Research
Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 20201
Table 2
Category | No. | No. (%) positive | No. (%) negative | Seroprevalence (95% CrI) | Relative risk (95% CrI) |
---|---|---|---|---|---|
Overall |
1,840 |
411 (22.3) |
1,429 (77.7) |
38.3 (31.8–46.5) |
|
Age, y | |||||
1–4 | 68 | 20 (29.4) | 48 (70.6) | 43 (31.3–56.1) | 1.30 (0.96–1.71) |
5–9 | 224 | 52 (23.2) | 172 (76.8) | 39.3 (29.5–51.1) | 1.19 (0.92–1.51) |
10–19 | 448 | 124 (27.7) | 324 (72.3) | 44.9 (36.3–56) | 1.36 (1.11–1.66) |
20–29 | 459 | 89 (19.4) | 370 (80.6) | 33.3 (25.6–42) | Referent |
30–39 | 307 | 52 (16.9) | 255 (83.1) | 30 (21.9–39.3) | 0.91 (0.68–1.17) |
40–49 | 139 | 26 (18.7) | 113 (81.3) | 33.2 (22.8–45.6) | 1.00 (0.71–1.35) |
50–64 | 120 | 31 (25.8) | 89 (74.2) | 42.8 (30.6–57.6) | 1.29 (0.94–1.73) |
65–84 |
75 |
17 (22.7) |
58 (77.3) |
38.8 (25.2–54.8) |
1.17 (0.78–1.63) |
Sex | |||||
F | 1,149 | 260 (22.6) | 889 (77.4) | 33.3 (25.6–42) | Referent |
M | 691 | 151 (21.9) | 540 (78.1) | 31.7 (23.6–41.2) | 0.95 (0.81–1.12) |
*NA, not available; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
1A portion of this research was presented at the United States–Japan Cooperative Medical Sciences Program—Virtual Workshop on COVID-19, February 24–26, 2021.
2These authors contributed equally to this article.
3These authors contributed equally to this article.
Page created: March 25, 2021
Page updated: May 18, 2021
Page reviewed: May 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.